The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
Publications
Fatal, gold-induced pneumonitis.
Rheumatology international 2003 Jul;23;207-10 — 2003 Jul — 207-10
Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.
Intensive care medicine 1998 Oct;24;1110-2 — 1998 Oct — 1110-2
Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.
American journal of respiratory and critical care medicine 1997 Mar;155;1011-20 — 1997 Mar — 1011-20
Reversal of progressive, life-threatening gold hypersensitivity pneumonitis by corticosteroids.
The American journal of medicine 1981 Nov;71;908-12 — 1981 Nov — 908-12
Relationship of gold and penicillamine therapy to diffuse interstitial lung disease.
Annals of the rheumatic diseases 1981 Apr;40;136-41 — 1981 Apr — 136-41
Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role.
Acta oto-laryngologica 1992;112;370-5 — 1992 — 370-5
Diffuse pulmonary injury associated with gold treatment.
The New England journal of medicine 1976 Apr 22;294;919-21 — 1976 Apr 22 — 919-21